Search
Menu
Home
HTB
2019
August
HTB
August 2019
Contents
Editorial
HTB 23 August 2019 online: second reports from IAS 2019
Special reports
Fit for purpose: antiretroviral treatment optimisation
Conference reports
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
Dolutegravir for younger children: results from the ODYSSEY trial
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
Antiretrovirals
Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA
PDFs
23 August 2019 vol 20 no 10